Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Formative Research

Date Submitted: Jun 20, 2022
Date Accepted: Feb 14, 2023

The final, peer-reviewed published version of this preprint can be found here:

Patient Feedback on a Mobile Medication Adherence App for Buprenorphine and Naloxone: Closed and Open-Ended Survey on Feasibility and Acceptability

Smith CL, Keever A, Bowden T, Olson K, Rodin N, McDonell MG, Roll JM, Smoody G, LeBrun J, Miguel AQ, McPherson SM

Patient Feedback on a Mobile Medication Adherence App for Buprenorphine and Naloxone: Closed and Open-Ended Survey on Feasibility and Acceptability

JMIR Form Res 2023;7:e40437

DOI: 10.2196/40437

PMID: 37074780

PMCID: 10157459

Patient Feedback on a Mobile Medication Adherence Application for Buprenorphine/Naloxone: Feasibility and Acceptability Study

  • Crystal L. Smith; 
  • Abigail Keever; 
  • Theresa Bowden; 
  • Katie Olson; 
  • Nicole Rodin; 
  • Michael G. McDonell; 
  • John M. Roll; 
  • Gillian Smoody; 
  • Jeff LeBrun; 
  • Andre Q.C. Miguel; 
  • Sterling M. McPherson

ABSTRACT

Background:

Opioid use disorders (OUD) impact the health and well-being of millions of Americans. Buprenorphine or buprenorphine/naloxone (BUP/NAL) can reduce opioid overdose deaths, decrease misuse, and improve quality of life. Unfortunately, poor medication adherence is a primary barrier to long-term efficacy of BUP/NAL.

Objective:

The intent of this investigation was to examine qualitative and quantitative patient feedback on a Bluetooth-enabled pill bottle cap and associated mobile application for patients prescribed BUP/NAL for an OUD.

Methods:

A convenience sample at an OUD outpatient clinic were asked about medication adherence, opioid cravings, experience with technology, and their existent support system through a brief, electronic survey. Patients also provided detailed feedback on features being considered for inclusion in a new technology designed to increase medication adherence, such as inclusion of a personal motivational factor, craving and stress tracking, incentives, and virtual coaching.

Results:

Twenty people (n=20) with an OUD who were prescribed BUP/NAL participated. Participants mean age was 34 years, 65% were female, and 80% Caucasian. Participants had the opportunity to select the most useful, second most useful, and least useful features presented; the large majority indicated that motivational reminders would be most useful (42.1%), followed by craving and stress tracking (26.3%) and online support forums (21.1%).

Conclusions:

Incorporating these suggestions for the described pill-bottle technology may encourage the use of the platform, as well as allow technology developers and BUP/NAL providers to modify this tool for different patient populations. Clinical Trial: N/A


 Citation

Please cite as:

Smith CL, Keever A, Bowden T, Olson K, Rodin N, McDonell MG, Roll JM, Smoody G, LeBrun J, Miguel AQ, McPherson SM

Patient Feedback on a Mobile Medication Adherence App for Buprenorphine and Naloxone: Closed and Open-Ended Survey on Feasibility and Acceptability

JMIR Form Res 2023;7:e40437

DOI: 10.2196/40437

PMID: 37074780

PMCID: 10157459

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.